Eli Lilly receives FDA approval for eczema treatment Ebglyss

Eli Lilly has received FDA approval for Ebglyss, a new treatment for moderate-to-severe eczema, specifically targeting patients aged 12 and older who have not found relief with topical therapies. This treatment is administered through monthly injections and works by inhibiting IL-13, a key player in eczema inflammation. Clinical trials demonstrated significant efficacy, with 38% of participants achieving clear or almost clear skin after 16 weeks, compared to just 12% in the placebo group. The approval was based on data from three pivotal studies involving over 1,000 participants. The studies measured the primary endpoint of clear skin at 16 weeks, with many patients also reporting itch relief. Notably, 77% of those who achieved clear skin maintained their results after one year with monthly dosing. The treatment regimen begins with an initial dose of 500 mg, followed by maintenance doses of 250 mg every four weeks. Ebglyss not only addresses the physical symptoms of eczema but also aims to improve the quality of life for patients suffering from this chronic condition. The results indicate that a significant portion of patients can expect long-term benefits from the treatment, which is crucial for those who have struggled with inadequate control of their symptoms. This approval marks a significant advancement in eczema treatment options, providing hope for patients who have not responded well to existing therapies. Eli Lilly's commitment to developing innovative solutions in dermatology is further underscored by this achievement, potentially transforming the management of moderate-to-severe eczema.